Pfizer is reportedly among a clutch of drug makers said to have been summoned to provide information in China's latest investigation of drug prices, which has apparently been prompted by rising public complaints over medicine costs. Chinese regulators could also impose hefty new fines on multinationals if they refuse to provide relevant materials or information, under a draft of revised antitrust regulation.

Shanghai Fosun Pharmaceutical Group is continuing on an acquisitive streak with a plan to buy an initial 65% stake in Suzhou Erye Pharmaceutical, and may eventually fully acquire the company in a deal worth nearly $250 million in total.

The vice president for Medical Affairs discusses the recent Chindex Internationa merger, the challenges and opportunities that the company faces to meet the need for more private health care, as the central government ramps up spending and attitudes toward health insurance and medical incentives change.

The vice president for Medical Affairs discusses the recent Chindex International merger, the challenges and opportunities that the company faces to meet the need for more private health care, as the central government ramps up spending and attitudes toward health insurance and medical incentives change.